Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparison of the proportions of Secondary Progressive Multiple Sclerosis between three registries within the SPMS Research Collaboration Network
Multiple Sclerosis
P4 - Poster Session 4 (5:30 PM-6:30 PM)
9-011
To identify and highlight differences in Secondary Progressive Multiple Sclerosis (SPMS) prevalence in three European multiple sclerosis (MS) registries.
There is significant uncertainty and a lack of scientific information to enable characterisation of the prevalence and course of SPMS in different populations. We therefore sought to use real world data from three clinical MS registries in Europe to enhance current understanding.
Data from MS registries in Germany, United Kingdom (UK) and Sweden were used. Inclusion criteria were patients with relapsing remitting MS (RRMS) or SPMS, age ≥ 18 years at the beginning of the study period (01/2016-10/2019). We included 21,552 German patients, 3,486 UK patients and 11,907 Swedish patients. The SPMS proportion was calculated at the end of the study period and only patients with at least one Expanded Disability Status Scale (EDSS) score during the study period were included. An SPMS decision tree classifier (Ramanujam, et al., 2016. P897, ECTRIMS), previously trained on Swedish data with age and EDSS as input variables, was used. The predicted phenotype from the classifier was compared with clinically assigned MS courses (RRMS vs SPMS).
The clinically assigned SPMS proportion was 16.6% for Germany, 13.8% in the UK and 24.5% in Sweden. After applying the decision tree classifier to the patients’ latest EDSS score and age, the SPMS proportion increased to 26.2% in Germany, 35.6% in UK and 25.4% in Sweden.
There were striking differences in the proportion of clinically assigned SPMS between the three registries. By applying a classifier that allowed for reclassification of RRMS/SPMS patients, the SPMS proportions increased dramatically in the validation datasets and became more comparable. Our findings suggest that the size of the SPMS population may be substantially underestimated when clinically assigned courses are used. Further research is required to elaborate on these findings.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
Rod Middleton (Data Scienve Building) The institution of Mr. Middleton has received research support from MS Society.
No disclosure on file
Jeff Rodgers Jeff Rodgers has nothing to disclose.
Richard S. Nicholas, FRCP (Imperial College Healthcare Trust) Dr. Nicholas has nothing to disclose.
No disclosure on file
Ali Manouchehrinia, PhD (Karolinska Institutet) Dr. Manouchehrinia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Manouchehrinia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Manouchehrinia has received research support from Karolinska Institutet.
No disclosure on file
No disclosure on file
No disclosure on file
Thomas Hach Thomas Hach has received personal compensation for serving as an employee of Novartis Pharma AG. Thomas Hach has received stock or an ownership interest from Novartis.
No disclosure on file
Jan A. Hillert, MD (Karolinska Institute, Neurology R54) Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche.